GlaxoSmithKline (GSK) is axing 130 ‘non-core’ brands and overhauling its prescription drugs business to focus on products that deliver stronger returns.
It is also stepping up a cost reduction program that has already bitten into media and marketing budgets across the consumer healthcare portfolio.
{iframe}http://www.adnews.com.au/news/glaxosmithkline-to-axe-130-brands-and-overhaul-pharma-business{/iframe}